AstraZeneca PLC second quarter and half year results 2013
- Details
- Category: AstraZeneca
AstraZeneca has announced that the revenue in the second quarter declined by 4 percent at constant exchange rates (CER), as the impact from products with recent loss of exclusivity has moderated from the levels experienced in recent quarters. Revenue for the rest of the portfolio was up 4 percent, fuelled by a double-digit increase from the five growth platforms.
GSK adds to its commitment to GAVI Alliance to help protect millions more children against infectious diseases
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) has increased its commitment to the GAVI Alliance to provide vaccines to developing countries, helping to protect millions more children against infectious diseases. Under this new agreement, GSK will provide an additional 240 million doses of Synflorix™ to developing countries over the next ten years, helping protect up to 80 million more children from pneumococcal diseases such as meningitis and pneumonia.
Pfizer to create separate, internal, global Innovative and Value businesses
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) has announced plans to move forward to internally separate its commercial operations into three business segments, two of which will include Innovative business lines and a third which will include the Value business line. Each of the three segments will include developed markets and emerging markets.
Bristol-Myers Squibb and Samsung BioLogics announce biopharmaceutical manufacturing relationship
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Samsung BioLogics today announced the companies have entered into a 10-year agreement under which Samsung BioLogics will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its recently completed plant in Songdo Incheon, South Korea.
Pfizer statement on PhRMA-EFPIA principles for responsible clinical trial data sharing
- Details
- Category: Pfizer
The Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have published new commitments for responsible data sharing practices by biopharmaceutical companies. The new commitments are designed to expand access to clinical trial data and advance science.
Bristol-Myers Squibb reports second quarter 2013 financial results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) today reported results for the second quarter of 2013 highlighted by the resubmission of Forxiga in the U.S., the completion of regulatory filings for Eliquis and Metreleptin in the U.S., and the presentation of important data from its immuno-oncology franchise at ASCO, for Orencia® at EULAR and for Eliquis at ISTH.
AstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application
- Details
- Category: AstraZeneca
AstraZeneca and Bristol-Myers Squibb today announced they have resubmitted to the U.S. Food and Drug Administration (FDA), a New Drug Application (NDA) for dapagliflozin for the treatment of adults with type 2 diabetes. The NDA resubmission, which is pending acceptance by the FDA, includes several new studies and additional long-term data (up to four years' duration) from previously submitted studies.
More Pharma News ...
- Novartis delivered growth across all divisions in second quarter
- Benefits of Pradaxa® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure
- GSK announces US submission for dabrafenib/trametinib combination in metastatic melanoma
- Roche halts investigation of aleglitazar
- AstraZeneca collaborates with Cambridge medical research institutions to advance cancer research
- Novartis and Biological E agree to deliver affordable vaccines for typhoid and paratyphoid A fevers to developing world
- GSK and Save the Children launch $1 million award to discover new healthcare innovations for reducing child deaths